Mildronate

weak data

Also seen as: Meldonium

The Dose Guy’s verdict

Sep 1, 2026
3 sources

Mildronate is a real metabolic drug with real cardiac trial data, just none of it Western and none of it large enough to close the argument. The mechanism is interesting and the safety profile is clean in what has been studied, but the endurance case everyone buys it for rests on inference, not a performance trial. If you are healthy and chasing a training edge, you are extrapolating from angina patients, and you should know that going in.

Would I take it?Interesting, but you're extrapolating.

What it is

A synthetic analog of carnitine, developed in Latvia and used across Eastern Europe as a cardiac drug since the 1980s. You know the name from doping headlines: WADA banned mildronate in 2016, and a wave of positive tests followed across dozens of sports. The mechanism is clean to hold. Your body uses L-carnitine to shuttle long-chain fatty acids into mitochondria for burning. Mildronate blocks carnitine synthesis and its transporter, forcing cells to lean on glucose instead, which uses less oxygen per unit of energy. In a heart starved for oxygen, that metabolic shift is protective. In an athlete, the hope is the same efficiency gain, plus a recovery edge that Eastern European sports medicine has believed in for decades.

Where it sits on this shelf: mildronate is a real pharmaceutical with prescription use across Latvia, Russia, and the former Soviet bloc, but it has never been submitted for FDA or EMA approval and Western trial data is thin. If you want the other performance angle, roxadustat works the EPO side instead of the metabolic one, and it is also banned in sport.

What the research shows

The clinical data is cardiac, Eastern European, and moderate in size. Enough to show the drug does something, not enough to satisfy a Western regulator:

Mildronate 1000 mg daily added to standard angina therapy increased total bicycle exercise time by a mean 35.18 seconds versus placebo at week 12, p=0.002. The 100 mg and 300 mg arms did not separate from placebo, and 3000 mg produced a smaller increase than 1000 mg.MILSS I · phase 2 · n=512

In healthy volunteers taking 500 mg twice daily for 4 weeks, mean plasma L-carnitine fell 18% and gamma-butyrobetaine rose about two-fold, confirming the metabolic shift in people.J Pharm Pharmacol 2011 · healthy volunteers

Adding mildronate for 12 weeks after a heart attack reduced angina attacks, ventricular extrasystoles, and paroxysmal rhythm disturbances, with p values of 0.001, 0.002, and 0.001.Post-MI RCT 2016 · n=67

No trial has tested mildronate for exercise performance in healthy athletes. The endurance case is mechanistic inference from cardiac data and decades of Eastern European sports-medicine practice, not a controlled result.as of Aug 2026

Realistic protocols

The clinical protocol across Eastern Europe is 500 to 1000 mg oral daily, with 1000 mg the ceiling supported by the trial data. The standard pattern is a course of 4 to 6 weeks, sometimes preceded by a short IV loading phase in clinical settings, though the community runs it orally from day one.

Take it in the morning, because dosing late can interfere with sleep. Some people split to twice daily, but once daily covers most. Do not stack mildronate with L-carnitine: the whole mechanism works by lowering carnitine, so supplementing carnitine at the same time fights the drug’s own action. If you want both in your toolkit, run them in separate blocks.

Standard500–1000 mg/dayOral, morning. Higher doses did not beat 1000 mg in the trial.

Duration4–6 weeksCourse-based, not indefinite. Reassess between runs.

AvoidNo L-carnitineCarnitine reverses the mechanism. Run them in separate blocks.

Side effects

Clean in every published trial, though the data is short-term and mostly in cardiac patients:

commonGI discomfort and occasional headache, rare and mild in the trials.

monitorThe carnitine suppression is the mechanism, not a side effect, but chronic suppression in a healthy person is unstudied. Keep courses bounded.

monitorIf you compete in tested sport, know the detection window. Urinary meldonium stayed above 10 ng/mL for up to 65 days after a single 500 mg dose and 117 days after 500 mg twice daily for six days. One course can flag a test months later.

anecdotalSome users report a subtle stimulant-like feel, consistent with the metabolic shift toward glucose.

unknownLong-term safety in healthy, non-cardiac users has never been studied. The drug was developed for sick hearts, not healthy athletes.